These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35072488)

  • 1. Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain.
    Cooper AJ; Gainor JF
    J Clin Oncol; 2022 Mar; 40(7):693-697. PubMed ID: 35072488
    [No Abstract]   [Full Text] [Related]  

  • 2. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
    JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Young male with fanconi anemia and EGFR-mutant non-small-cell lung cancer.
    Cathcart-Rake E; Lopez-Chavez A
    J Thorac Oncol; 2014 Nov; 9(11):e83-5. PubMed ID: 25436812
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence of mutation in the epidermal growth factor receptor gene in Chinese patients with non-small cell lung cancer.
    Jiang B; Zhu ZZ; Liu F; Hou LF; Gu J; Chen E; Tzeng CM; Zhu G
    Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):635. PubMed ID: 17051955
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
    Lai RS; Xie L; Shen LS; He YM; Zhu CL
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
    [No Abstract]   [Full Text] [Related]  

  • 6. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor immune microenvironment of
    Matsumoto Y; Koh Y
    Immunotherapy; 2020 May; 12(7):431-437. PubMed ID: 32316809
    [No Abstract]   [Full Text] [Related]  

  • 8. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
    Zhang H; Zhang S
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):61-65. PubMed ID: 28103975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
    Haddad FG; Kourie HR; Kattan J
    Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
    [No Abstract]   [Full Text] [Related]  

  • 10. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
    Hata A; Masago K; Katakami N; Imai Y; Yatabe Y
    J Thorac Oncol; 2014 Aug; 9(8):e64-5. PubMed ID: 25157783
    [No Abstract]   [Full Text] [Related]  

  • 13. Her2-neu: a target in lung cancer?
    Andre F; Le Chevalier T; Soria JC
    Ann Oncol; 2004 Jan; 15(1):3-4. PubMed ID: 14679110
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
    Jänne PA
    J Clin Oncol; 2006 Jul; 24(21):3319-21. PubMed ID: 16785470
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
    Heuckmann JM; Rauh D; Thomas RK
    J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
    Álvarez-Fernández C; Esteban-González E
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():2-6. PubMed ID: 27426241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
    Cappuzzo F; Bemis L; Varella-Garcia M
    N Engl J Med; 2006 Jun; 354(24):2619-21. PubMed ID: 16775247
    [No Abstract]   [Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current management and future prospect of HER-2 mutant non-small cell lung cancer].
    Xu F; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):829-837. PubMed ID: 33113623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.